| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 26 | 2023 | 342 | 6.380 |
Why?
|
| Coronary Artery Disease | 26 | 2023 | 1011 | 4.800 |
Why?
|
| Coronary Artery Bypass | 18 | 2023 | 708 | 3.730 |
Why?
|
| ST Elevation Myocardial Infarction | 12 | 2023 | 105 | 3.020 |
Why?
|
| Acute Coronary Syndrome | 11 | 2022 | 259 | 2.870 |
Why?
|
| Drug-Eluting Stents | 7 | 2019 | 131 | 2.390 |
Why?
|
| Transcatheter Aortic Valve Replacement | 11 | 2023 | 314 | 2.290 |
Why?
|
| Aortic Valve Stenosis | 10 | 2023 | 476 | 2.100 |
Why?
|
| Myocardial Infarction | 18 | 2023 | 1374 | 1.800 |
Why?
|
| Coronary Stenosis | 3 | 2022 | 117 | 1.570 |
Why?
|
| Hospital Mortality | 10 | 2023 | 1274 | 1.540 |
Why?
|
| Coronary Angiography | 12 | 2023 | 598 | 1.540 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2012 | 314 | 1.470 |
Why?
|
| Electrocardiography | 7 | 2022 | 1145 | 1.460 |
Why?
|
| Stroke | 14 | 2023 | 1144 | 1.390 |
Why?
|
| Kidney Failure, Chronic | 6 | 2023 | 960 | 1.350 |
Why?
|
| Peripheral Arterial Disease | 5 | 2024 | 267 | 1.330 |
Why?
|
| Myocardial Revascularization | 6 | 2022 | 134 | 1.220 |
Why?
|
| Coronary Vessels | 6 | 2023 | 665 | 1.170 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2020 | 435 | 1.110 |
Why?
|
| Registries | 10 | 2021 | 2170 | 1.100 |
Why?
|
| Atrial Fibrillation | 6 | 2021 | 719 | 1.080 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2023 | 444 | 0.970 |
Why?
|
| Postoperative Complications | 10 | 2021 | 5542 | 0.970 |
Why?
|
| Metal Nanoparticles | 2 | 2022 | 164 | 0.920 |
Why?
|
| Catheterization, Peripheral | 2 | 2023 | 158 | 0.920 |
Why?
|
| Stents | 4 | 2019 | 1096 | 0.890 |
Why?
|
| Risk Factors | 40 | 2023 | 17523 | 0.890 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2022 | 849 | 0.880 |
Why?
|
| Daucus carota | 1 | 2022 | 5 | 0.880 |
Why?
|
| Zinc Oxide | 1 | 2022 | 10 | 0.870 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2021 | 323 | 0.860 |
Why?
|
| Cardiovascular Diseases | 13 | 2023 | 2195 | 0.860 |
Why?
|
| Treatment Outcome | 48 | 2023 | 32848 | 0.840 |
Why?
|
| Angioplasty, Balloon | 1 | 2022 | 183 | 0.790 |
Why?
|
| Atrial Appendage | 1 | 2021 | 55 | 0.780 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 160 | 0.780 |
Why?
|
| Thrombolytic Therapy | 2 | 2020 | 257 | 0.760 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2019 | 25 | 0.750 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2022 | 192 | 0.730 |
Why?
|
| Humans | 129 | 2024 | 261506 | 0.730 |
Why?
|
| Heart Transplantation | 2 | 2021 | 908 | 0.720 |
Why?
|
| Heart Valve Prosthesis Implantation | 6 | 2022 | 563 | 0.700 |
Why?
|
| Shock, Cardiogenic | 6 | 2023 | 228 | 0.690 |
Why?
|
| Drug Utilization | 2 | 2020 | 179 | 0.690 |
Why?
|
| Ultrasonic Therapy | 1 | 2019 | 55 | 0.690 |
Why?
|
| Colchicine | 3 | 2021 | 52 | 0.680 |
Why?
|
| Atherosclerosis | 6 | 2024 | 935 | 0.660 |
Why?
|
| Seasons | 3 | 2005 | 340 | 0.640 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 163 | 0.630 |
Why?
|
| Heart Septum | 2 | 2009 | 54 | 0.620 |
Why?
|
| Echocardiography | 8 | 2020 | 1182 | 0.610 |
Why?
|
| Fibrinolytic Agents | 2 | 2019 | 324 | 0.600 |
Why?
|
| Pericarditis | 2 | 2020 | 61 | 0.590 |
Why?
|
| Inpatients | 5 | 2022 | 678 | 0.580 |
Why?
|
| Cocaine | 1 | 2018 | 233 | 0.570 |
Why?
|
| Femoral Artery | 4 | 2023 | 210 | 0.550 |
Why?
|
| Risk Assessment | 13 | 2021 | 6869 | 0.550 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 329 | 0.540 |
Why?
|
| Ethanol | 2 | 2009 | 264 | 0.540 |
Why?
|
| Aortic Valve | 9 | 2023 | 581 | 0.530 |
Why?
|
| Hemorrhage | 6 | 2023 | 712 | 0.530 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2023 | 787 | 0.520 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2022 | 1237 | 0.520 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 160 | 0.500 |
Why?
|
| Stroke Volume | 5 | 2021 | 577 | 0.500 |
Why?
|
| Cardiac Catheterization | 7 | 2022 | 687 | 0.490 |
Why?
|
| Ventricular Function, Left | 2 | 2021 | 603 | 0.480 |
Why?
|
| Male | 63 | 2023 | 123000 | 0.470 |
Why?
|
| Aged | 41 | 2023 | 70117 | 0.460 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2014 | 112 | 0.460 |
Why?
|
| Propensity Score | 3 | 2021 | 750 | 0.450 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 516 | 0.440 |
Why?
|
| Robotic Surgical Procedures | 1 | 2019 | 481 | 0.430 |
Why?
|
| Drug Prescriptions | 5 | 2020 | 289 | 0.420 |
Why?
|
| Hypertension | 5 | 2023 | 1503 | 0.420 |
Why?
|
| Catheter Ablation | 2 | 2009 | 620 | 0.420 |
Why?
|
| Medication Adherence | 4 | 2021 | 492 | 0.420 |
Why?
|
| Female | 63 | 2023 | 141928 | 0.410 |
Why?
|
| Vascular Grafting | 1 | 2012 | 50 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2022 | 2594 | 0.410 |
Why?
|
| Saphenous Vein | 1 | 2012 | 95 | 0.400 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2021 | 16 | 0.400 |
Why?
|
| Cause of Death | 2 | 2021 | 752 | 0.400 |
Why?
|
| Middle Aged | 43 | 2023 | 86204 | 0.390 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 257 | 0.370 |
Why?
|
| Feces | 2 | 2005 | 770 | 0.370 |
Why?
|
| Incidental Findings | 2 | 2009 | 272 | 0.370 |
Why?
|
| Sex Factors | 7 | 2021 | 2139 | 0.370 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 739 | 0.370 |
Why?
|
| Renal Insufficiency | 2 | 2011 | 321 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 2403 | 0.340 |
Why?
|
| Vascular Diseases | 2 | 2022 | 246 | 0.340 |
Why?
|
| Sex Characteristics | 1 | 2012 | 417 | 0.340 |
Why?
|
| Sclerotherapy | 1 | 2009 | 48 | 0.340 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2013 | 410 | 0.330 |
Why?
|
| Vena Cava, Superior | 1 | 2009 | 78 | 0.330 |
Why?
|
| Logistic Models | 5 | 2021 | 3441 | 0.330 |
Why?
|
| Time Factors | 11 | 2022 | 12926 | 0.320 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 257 | 0.310 |
Why?
|
| United States | 17 | 2023 | 15433 | 0.310 |
Why?
|
| Sarcoidosis | 1 | 2009 | 112 | 0.310 |
Why?
|
| Heart Arrest | 2 | 2023 | 358 | 0.310 |
Why?
|
| Retrospective Studies | 18 | 2022 | 37905 | 0.300 |
Why?
|
| Tyrosine | 1 | 2009 | 498 | 0.300 |
Why?
|
| Odds Ratio | 4 | 2020 | 2316 | 0.300 |
Why?
|
| Coronary Vessel Anomalies | 3 | 2022 | 300 | 0.300 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2020 | 151 | 0.290 |
Why?
|
| Anticoagulants | 3 | 2021 | 787 | 0.290 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 1303 | 0.290 |
Why?
|
| Severity of Illness Index | 9 | 2020 | 4320 | 0.280 |
Why?
|
| Pakistan | 9 | 2009 | 77 | 0.280 |
Why?
|
| Coronary Circulation | 2 | 2019 | 253 | 0.270 |
Why?
|
| Heart Failure | 6 | 2022 | 2516 | 0.270 |
Why?
|
| Spasm | 2 | 2023 | 59 | 0.270 |
Why?
|
| Diastole | 3 | 2020 | 187 | 0.260 |
Why?
|
| Radial Artery | 2 | 2023 | 50 | 0.260 |
Why?
|
| Vibrio cholerae | 1 | 2004 | 31 | 0.250 |
Why?
|
| Morbidity | 2 | 2019 | 397 | 0.250 |
Why?
|
| Cholera | 1 | 2004 | 27 | 0.250 |
Why?
|
| Obesity | 3 | 2021 | 2884 | 0.250 |
Why?
|
| Comorbidity | 8 | 2024 | 2352 | 0.250 |
Why?
|
| Hypoglycemic Agents | 2 | 2020 | 586 | 0.250 |
Why?
|
| Gram-Negative Bacteria | 1 | 2005 | 100 | 0.250 |
Why?
|
| Hematoma | 2 | 2023 | 160 | 0.240 |
Why?
|
| Aged, 80 and over | 15 | 2023 | 29902 | 0.240 |
Why?
|
| Life Style | 3 | 2023 | 612 | 0.240 |
Why?
|
| Heart Valve Diseases | 2 | 2017 | 193 | 0.240 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 546 | 0.240 |
Why?
|
| Prescription Drugs | 2 | 2014 | 64 | 0.230 |
Why?
|
| Thiophenes | 2 | 2014 | 148 | 0.230 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2005 | 158 | 0.230 |
Why?
|
| Secondary Prevention | 3 | 2021 | 329 | 0.230 |
Why?
|
| Warfarin | 2 | 2021 | 152 | 0.230 |
Why?
|
| Guideline Adherence | 4 | 2020 | 636 | 0.230 |
Why?
|
| Coronary Occlusion | 1 | 2023 | 31 | 0.220 |
Why?
|
| No-Reflow Phenomenon | 2 | 2019 | 9 | 0.220 |
Why?
|
| Reducing Agents | 1 | 2022 | 1 | 0.220 |
Why?
|
| Cardiomyopathies | 1 | 2009 | 610 | 0.220 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2022 | 34 | 0.220 |
Why?
|
| Heart-Assist Devices | 2 | 2022 | 1171 | 0.220 |
Why?
|
| Hyperlipidemias | 2 | 2021 | 235 | 0.220 |
Why?
|
| Popliteal Artery | 1 | 2022 | 52 | 0.220 |
Why?
|
| Body Mass Index | 2 | 2021 | 2203 | 0.210 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2022 | 68 | 0.210 |
Why?
|
| Age Factors | 3 | 2021 | 5377 | 0.210 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2022 | 180 | 0.210 |
Why?
|
| Silver | 1 | 2022 | 34 | 0.210 |
Why?
|
| X-Ray Diffraction | 1 | 2022 | 168 | 0.210 |
Why?
|
| Vascular Patency | 1 | 2022 | 218 | 0.210 |
Why?
|
| Molecular Docking Simulation | 1 | 2022 | 144 | 0.210 |
Why?
|
| Adult | 24 | 2023 | 77950 | 0.210 |
Why?
|
| Diabetes Mellitus | 4 | 2023 | 1054 | 0.200 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2010 | 592 | 0.200 |
Why?
|
| Marijuana Use | 1 | 2021 | 10 | 0.200 |
Why?
|
| Unsafe Sex | 1 | 2021 | 21 | 0.200 |
Why?
|
| Conservative Treatment | 1 | 2021 | 58 | 0.200 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2021 | 42 | 0.200 |
Why?
|
| Endocarditis, Bacterial | 3 | 2009 | 128 | 0.190 |
Why?
|
| Vaping | 1 | 2021 | 33 | 0.190 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2018 | 48 | 0.190 |
Why?
|
| Time | 1 | 2021 | 178 | 0.190 |
Why?
|
| Inferior Wall Myocardial Infarction | 1 | 2020 | 8 | 0.190 |
Why?
|
| Veterans Health | 2 | 2020 | 181 | 0.190 |
Why?
|
| Bacteria | 3 | 2009 | 611 | 0.190 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2021 | 136 | 0.190 |
Why?
|
| Plant Extracts | 1 | 2022 | 215 | 0.180 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 88 | 0.180 |
Why?
|
| Follow-Up Studies | 9 | 2019 | 14889 | 0.180 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2023 | 253 | 0.180 |
Why?
|
| Age of Onset | 2 | 2021 | 827 | 0.180 |
Why?
|
| Bioprosthesis | 1 | 2021 | 167 | 0.180 |
Why?
|
| Prescriptions | 1 | 2019 | 65 | 0.170 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2020 | 50 | 0.170 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 103 | 0.170 |
Why?
|
| Endocarditis | 1 | 2020 | 125 | 0.170 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 605 | 0.170 |
Why?
|
| Aspirin | 3 | 2022 | 455 | 0.170 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 994 | 0.170 |
Why?
|
| Microcirculation | 1 | 2019 | 200 | 0.170 |
Why?
|
| Office Visits | 1 | 2019 | 97 | 0.170 |
Why?
|
| Multimorbidity | 1 | 2018 | 22 | 0.170 |
Why?
|
| Bisoprolol | 1 | 2018 | 11 | 0.170 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2019 | 78 | 0.170 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 462 | 0.170 |
Why?
|
| Atenolol | 1 | 2018 | 42 | 0.160 |
Why?
|
| Propanolamines | 1 | 2018 | 44 | 0.160 |
Why?
|
| Metoprolol | 1 | 2018 | 28 | 0.160 |
Why?
|
| In Vitro Techniques | 2 | 2013 | 1618 | 0.160 |
Why?
|
| Alcoholism | 1 | 2021 | 285 | 0.160 |
Why?
|
| Thinness | 1 | 2019 | 82 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2021 | 291 | 0.160 |
Why?
|
| Fluoroscopy | 1 | 2019 | 232 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 598 | 0.160 |
Why?
|
| Leukocyte Count | 1 | 2019 | 684 | 0.160 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 341 | 0.160 |
Why?
|
| Incretins | 1 | 2018 | 25 | 0.160 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 239 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 292 | 0.160 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2017 | 7 | 0.160 |
Why?
|
| Hospitalization | 3 | 2023 | 2083 | 0.160 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 60 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 527 | 0.160 |
Why?
|
| Diabetic Angiopathies | 2 | 2021 | 78 | 0.160 |
Why?
|
| Propranolol | 1 | 2018 | 156 | 0.150 |
Why?
|
| Chest Pain | 1 | 2018 | 155 | 0.150 |
Why?
|
| Brain Ischemia | 1 | 2020 | 292 | 0.150 |
Why?
|
| Dyslipidemias | 1 | 2020 | 235 | 0.150 |
Why?
|
| Primary Prevention | 2 | 2021 | 255 | 0.150 |
Why?
|
| Off-Label Use | 1 | 2017 | 46 | 0.150 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 386 | 0.150 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 635 | 0.140 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 473 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2018 | 145 | 0.140 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 128 | 0.140 |
Why?
|
| Pneumonia | 2 | 2020 | 751 | 0.140 |
Why?
|
| Balloon Valvuloplasty | 1 | 2016 | 31 | 0.140 |
Why?
|
| Antifungal Agents | 1 | 2022 | 834 | 0.140 |
Why?
|
| Length of Stay | 3 | 2023 | 1900 | 0.140 |
Why?
|
| Prognosis | 9 | 2022 | 21713 | 0.140 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2017 | 167 | 0.130 |
Why?
|
| Monocytes | 1 | 2019 | 788 | 0.130 |
Why?
|
| Pericardial Window Techniques | 1 | 2015 | 6 | 0.130 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 173 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2020 | 574 | 0.130 |
Why?
|
| Piperazines | 2 | 2014 | 2101 | 0.130 |
Why?
|
| Survival Rate | 4 | 2019 | 12221 | 0.130 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 33 | 0.130 |
Why?
|
| Bayes Theorem | 1 | 2019 | 1021 | 0.130 |
Why?
|
| Cardiac Tamponade | 1 | 2015 | 51 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 2265 | 0.130 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 4314 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2021 | 9244 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 2992 | 0.120 |
Why?
|
| Global Health | 1 | 2019 | 657 | 0.120 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 118 | 0.120 |
Why?
|
| Subclavian Artery | 1 | 2014 | 80 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2019 | 787 | 0.120 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2013 | 42 | 0.120 |
Why?
|
| Prevalence | 4 | 2019 | 3260 | 0.120 |
Why?
|
| Cell Survival | 1 | 2020 | 3045 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2020 | 945 | 0.110 |
Why?
|
| Pain | 1 | 2022 | 1658 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 429 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2020 | 1824 | 0.110 |
Why?
|
| Cardiology | 1 | 2019 | 530 | 0.110 |
Why?
|
| Stellate Ganglion | 1 | 2013 | 15 | 0.110 |
Why?
|
| Tachycardia, Sinus | 1 | 2013 | 12 | 0.110 |
Why?
|
| Mortality | 3 | 2021 | 343 | 0.110 |
Why?
|
| Systole | 1 | 2013 | 196 | 0.110 |
Why?
|
| Bundle-Branch Block | 2 | 2023 | 43 | 0.110 |
Why?
|
| Diuretics | 1 | 2013 | 170 | 0.110 |
Why?
|
| Hospitals, University | 4 | 2009 | 209 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 340 | 0.100 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 118 | 0.100 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 501 | 0.100 |
Why?
|
| Anesthetics, Local | 1 | 2013 | 163 | 0.100 |
Why?
|
| Texas | 4 | 2020 | 6311 | 0.100 |
Why?
|
| Metals | 1 | 2012 | 155 | 0.100 |
Why?
|
| Standard of Care | 1 | 2013 | 243 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1148 | 0.100 |
Why?
|
| Surgical Wound Infection | 2 | 2012 | 450 | 0.100 |
Why?
|
| Nerve Block | 1 | 2013 | 176 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2019 | 1112 | 0.100 |
Why?
|
| Culture Media | 2 | 2009 | 319 | 0.090 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2012 | 226 | 0.090 |
Why?
|
| Blood Pressure Determination | 1 | 2010 | 109 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2021 | 2218 | 0.090 |
Why?
|
| Biomarkers | 3 | 2020 | 5047 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2013 | 703 | 0.090 |
Why?
|
| Prospective Studies | 6 | 2015 | 12873 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 162 | 0.090 |
Why?
|
| Child, Preschool | 5 | 2020 | 16273 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2019 | 1467 | 0.090 |
Why?
|
| Preoperative Care | 2 | 2012 | 1529 | 0.090 |
Why?
|
| Consensus | 1 | 2013 | 978 | 0.090 |
Why?
|
| Syndrome | 1 | 2012 | 1351 | 0.080 |
Why?
|
| Syncope | 1 | 2009 | 64 | 0.080 |
Why?
|
| Adenosine Diphosphate | 1 | 2009 | 113 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 4892 | 0.080 |
Why?
|
| Platelet-Rich Plasma | 1 | 2009 | 25 | 0.080 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2009 | 71 | 0.080 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2009 | 100 | 0.080 |
Why?
|
| Aortography | 1 | 2009 | 181 | 0.080 |
Why?
|
| Adolescent | 6 | 2020 | 31252 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2019 | 9180 | 0.080 |
Why?
|
| Carotid Artery Diseases | 1 | 2009 | 196 | 0.080 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2009 | 216 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8865 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 330 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1362 | 0.080 |
Why?
|
| Bacterial Infections | 2 | 2009 | 479 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2013 | 1335 | 0.070 |
Why?
|
| Creatinine | 1 | 2009 | 531 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2021 | 1544 | 0.070 |
Why?
|
| Osteomalacia | 1 | 2006 | 36 | 0.070 |
Why?
|
| Reoperation | 2 | 2021 | 1382 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 500 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 1323 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 2843 | 0.070 |
Why?
|
| Frail Elderly | 1 | 2006 | 118 | 0.070 |
Why?
|
| Hip Fractures | 1 | 2006 | 76 | 0.070 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2004 | 16 | 0.060 |
Why?
|
| DNA | 1 | 2013 | 2693 | 0.060 |
Why?
|
| Serotyping | 1 | 2004 | 166 | 0.060 |
Why?
|
| Infant | 3 | 2005 | 13310 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2009 | 524 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 3719 | 0.060 |
Why?
|
| Ulnar Artery | 1 | 2023 | 11 | 0.060 |
Why?
|
| Intermittent Claudication | 1 | 2024 | 56 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 925 | 0.060 |
Why?
|
| Hypertension, Portal | 1 | 2004 | 124 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 7551 | 0.060 |
Why?
|
| Incidence | 3 | 2022 | 5673 | 0.050 |
Why?
|
| Students, Nursing | 1 | 2002 | 19 | 0.050 |
Why?
|
| Brain Diseases | 1 | 2006 | 403 | 0.050 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 9 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 1021 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 1697 | 0.050 |
Why?
|
| Agriculture | 1 | 2022 | 37 | 0.050 |
Why?
|
| Mitral Valve Stenosis | 1 | 2021 | 50 | 0.050 |
Why?
|
| Suicide, Assisted | 1 | 2001 | 19 | 0.050 |
Why?
|
| Tobacco, Smokeless | 1 | 2021 | 28 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 4549 | 0.050 |
Why?
|
| Anorexia | 1 | 2002 | 143 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 60 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2006 | 846 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2021 | 106 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 1085 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 2002 | 130 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2021 | 54 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 245 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2023 | 299 | 0.050 |
Why?
|
| Biopsy | 1 | 2009 | 3443 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 4988 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 62 | 0.050 |
Why?
|
| Ischemia | 1 | 2024 | 391 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2021 | 173 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2021 | 133 | 0.050 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 49 | 0.050 |
Why?
|
| Attitude | 1 | 2001 | 159 | 0.050 |
Why?
|
| Child | 4 | 2020 | 29154 | 0.050 |
Why?
|
| Rivaroxaban | 1 | 2020 | 59 | 0.050 |
Why?
|
| Gastroenteritis | 1 | 2003 | 300 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2022 | 271 | 0.050 |
Why?
|
| Angina, Stable | 1 | 2019 | 6 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 295 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 140 | 0.050 |
Why?
|
| HT29 Cells | 1 | 2020 | 159 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2006 | 1863 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2021 | 339 | 0.040 |
Why?
|
| Young Adult | 4 | 2021 | 21445 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 98 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2021 | 980 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 2019 | 109 | 0.040 |
Why?
|
| Diarrhea | 1 | 2003 | 686 | 0.040 |
Why?
|
| Algorithms | 1 | 2010 | 3890 | 0.040 |
Why?
|
| Veterans | 2 | 2021 | 1641 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 100 | 0.040 |
Why?
|
| Physicians, Primary Care | 1 | 2019 | 98 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2020 | 550 | 0.040 |
Why?
|
| Pyridones | 1 | 2020 | 348 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2021 | 551 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 658 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 249 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 548 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 142 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 565 | 0.040 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2018 | 197 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 14289 | 0.040 |
Why?
|
| Patient Selection | 2 | 2016 | 2055 | 0.040 |
Why?
|
| Students, Medical | 1 | 2002 | 399 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 1223 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 629 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 649 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2018 | 233 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2020 | 1643 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2018 | 161 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 1123 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 126 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 234 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 15694 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 918 | 0.030 |
Why?
|
| Pedigree | 1 | 2019 | 1890 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 524 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2019 | 554 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 1052 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 3472 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 498 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 4298 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 661 | 0.030 |
Why?
|
| Diet | 1 | 2021 | 1440 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 756 | 0.030 |
Why?
|
| Neoplasms | 1 | 2019 | 15193 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 1230 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2315 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 7702 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 2440 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2020 | 1471 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 4938 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 6207 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 4971 | 0.030 |
Why?
|
| Animals | 3 | 2022 | 59536 | 0.020 |
Why?
|
| Inflammation | 1 | 2020 | 2522 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 665 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 602 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 6009 | 0.020 |
Why?
|
| Kidney | 1 | 2018 | 2146 | 0.020 |
Why?
|
| Brain | 1 | 2022 | 4113 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 5539 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 652 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2009 | 397 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2010 | 561 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 4109 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 4758 | 0.020 |
Why?
|
| Blood | 1 | 2004 | 156 | 0.010 |
Why?
|
| Family Practice | 1 | 2001 | 125 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2001 | 120 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 11965 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 4744 | 0.010 |
Why?
|